SCPH - רווח נקי למניה (EPS TTM) scPharmaceuticals, Inc.

scPharmaceuticals Inc. possesses high growth potential driven by proprietary infusion systems that enable global sales expansion. Rolling trailing twelve-month net income per share reflects current dynamics, where the value of -1.81 serves as the current metric. The business remains crisis-resilient, as demand for heart failure therapy is stable. The company is currently aggressively implementing home-based treatment, displacing costly inpatient care.

Analyzing the change in TTM net income per share allows for an assessment of the efficiency of scPharmaceuticals Inc. (SCPH) within the high-tech drug distribution segment. This indicator reflects the final profit distributed across the total volume of shares, making it possible to identify a hidden decline in margins even amid sales growth, should the costs of complex pharmaceutical logistics begin to outpace revenue growth rates.